DICE THERAPEUTICS
DICE Therapeutics is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas... . The Companyโs DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICEโs lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting ฮฑ4ร7 integrin and ฮฑVร1/ฮฑVร6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
DICE THERAPEUTICS
Social Links:
Industry:
Biotechnology Medical Medical Device
Founded:
2013-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.dicetherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
(650) 566-1402
Email Addresses:
[email protected]
Total Funding:
187.38 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt IPv6 AJAX Libraries API COVID-19 JQuery CDN CloudFront New Relic
Similar Organizations
Black Diamond Therapeutics
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule.
BlueLight Therapeutics
BlueLight Therapeutics uses a proprietary structure-based platform to discover small molecules against difficult-to-drug targets.
CODA Biotherapeutics
CODA Biotherapeutics develops a chemogenetic platform designed to modulate neuronal activity.
Humacyte
Humacyte develops products for vascular diseases and replacement of anatomical conduits.
Intarcia Therapeutics
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
OxSonics Therapeutics
OxSonicsยฎ Therapeuticsโ proprietary drug delivery platform technology, SonoTranยฎ
Tarsa Therapeutics
Tarsa Therapeutics develops an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Eventide
Eventide investment in Series C - Dice Therapeutics
Logos Capital
Logos Capital investment in Series C - Dice Therapeutics
Soleus Capital
Soleus Capital investment in Series C - Dice Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series C - Dice Therapeutics
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series C - Dice Therapeutics
Asymmetry Capital Management
Asymmetry Capital Management investment in Series C - Dice Therapeutics
Driehaus Capital Management
Driehaus Capital Management investment in Series C - Dice Therapeutics
Northpond Ventures
Northpond Ventures investment in Series C - Dice Therapeutics
Sands Capital Ventures
Sands Capital Ventures investment in Series C - Dice Therapeutics
Deep Track Capital
Deep Track Capital investment in Series C - Dice Therapeutics
Official Site Inspections
http://www.dicetherapeutics.com Semrush global rank: 722.62 K Semrush visits lastest month: 56.89 K
- Host name: 43.142.223.35.bc.googleusercontent.com
- IP address: 35.223.142.43
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
